Estudos in silico e in vitro de novos candidatos a fármaco anticâncer
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora (UFJF)
Abstract
-Cancer is a term used for a group of highly complex malignant diseases that represent
an important public health problem. Glioblastoma Multiforme (GBM) is a tumor of the
central nervous system, with aggressive biological characteristics and high
invasiveness. It is known that GBM has biological resistance to several classes of
chemotherapy agents, with the drug temozolomide (TMZ) being the most used for
treatment. Another type of cancer that represents a significant challenge to global
health is breast cancer as it is the most frequently diagnosed cancer in the world and
the leading cause of mortality from this disease among women. The search for effective
drugs for the treatment of cancer that are selective for cancer cells is a challenge for
the scientific community. In this scenario, research for new anticancer drugs is
necessary in order to obtain more effective therapies that present fewer adverse
reactions. The general objective of this study was to select, synthesize and test new
quinazoline candidates for anticancer drugs and evaluate antitumor activity in GBM
(U87-MG and T98G) and breast cancer (MCF-7) tumor lines. For this, computational
studies were carried out that corroborated the selection of promising molecules with
good pharmacokinetic parameters to be synthesized. An initial in vitro test was carried
out to screen the synthesized molecules to evaluate their ability to inhibit cell viability
in glioblastoma tumor lines. Two molecules called KDY3 and KDY23 were the most
promising and quinazoline KDY3 was explored in this study. The inhibition of cell
viability promoted by KDY3 in GBM and breast cancer lines was significantly greater
than that promoted by temozolomide (TMZ) and doxorubicin (DOXO), which are
reference drugs for treatment of GBM and breast cancer. Differential expression
analysis of genes involved in cell survival pathways demonstrated that KDY3 acts
through different mechanisms than the drug TMZ. Therefore, KDY3 can be considered
a promising drug candidate for the treatment of GBM and breast cancer.
Description
Keywords
Citation
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acesso Aberto

